Key result
Azilsartan medoxomil reduced 24-hour mean ambulatory systolic blood pressure compared to telmisartan at 12 weeks in patients with hypertension.
Why the study?
Few studies have compared the safety and efficacy of azilsartan medoxomil and telmisartan in hypertensive patients, particularly using ambulatory blood pressure monitoring.
Does azilsartan medoxomil reduce blood pressure more effectively than telmisartan in hypertensive patients?
RCT (n=700)
Open-label, blinded endpoint
Simple randomization using chit-pull technique
No
Does azilsartan medoxomil reduce blood pressure more effectively than telmisartan in hypertensive patients?
Azilsartan medoxomil provides greater antihypertensive efficacy than telmisartan in reducing both 24-hour ambulatory and clinic blood pressure over 12 weeks, with a comparable safety profile.
Answers are grounded in this paper and cite their sources.
Azilsartan may be prioritized over telmisartan for hypertension; extends head-to-head ARB data with ambulatory monitoring.
BACKGROUND: Few studies have compared the safety and efficacy of azilsartan medoxomil (AZL-M) and telmisartan in hypertensive patients, especially using ambulatory blood pressure monitoring (ABPM). OBJECTIVE: The objective of this study was to compare the efficacy and safety profile of AZL-M and telmisartan in hypertensive patients using ABPM and clinic blood pressure (BP) monitoring. MATERIALS AND METHODS: This prospective, randomized, open-label, blinded endpoint, parallel-arm study included 700 patients, aged 18-70 years, with clinic and 24-h mean ambulatory systolic BP (SBP) of 150-180 mmHg and 130-170 mmHg, respectively. They were randomized equally into two groups: Group A received AZL-M 40 mg and Group T received telmisartan 40 mg; the dose was force titrated to 80 mg after 2 weeks if the response rate was not achieved. BP (clinical and ambulatory) was measured after 12 weeks and compared with baseline measurements. Headache was the most common adverse drug reaction (Group A: 21; Group T: 27) and fatigue the least. CONCLUSION: This study found that AZL-M has greater antihypertensive efficacy than telmisartan, with comparable side effects. In addition, ABPM was shown to be a feasible method for such studies.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2020) conducted an RCT in Hypertension (n=700). Azilsartan medoxomil vs. Telmisartan 40 mg daily, force titrated to 80 mg after 2 weeks if response rate not achieved was evaluated on Change in 24-h mean ambulatory systolic blood pressure at week 12 (p=<0.0001). Azilsartan medoxomil reduced 24-hour mean ambulatory systolic blood pressure compared to telmisartan at 12 weeks in patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: